STOCK TITAN

HAMILTON THORNE LTD ORD - HTLZF STOCK NEWS

Welcome to our dedicated page for HAMILTON THORNE ORD news (Ticker: HTLZF), a resource for investors and traders seeking the latest updates and insights on HAMILTON THORNE ORD stock.

Hamilton Thorne Ltd. (HTLZF) is a leading provider of precision instruments, consumables, software, and services in the Assisted Reproductive Technologies (ART) research and cell biology markets. The recent acquisition of Gynetics Medical Products strengthens the company's product offerings in the global IVF market. With Gynetics' revenues of approximately €4.6 million and Adjusted EBITDA of €2.3 million, Hamilton Thorne expands its presence in the European ART market, diversifies revenue streams, and enhances customer service quality.

Rhea-AI Summary

Hamilton Thorne reported strong Q3 2024 financial results with revenue growing 24% to $19.4 million and Adjusted EBITDA increasing 72% to $3.7 million. The company achieved 14% organic growth for the quarter, with equipment sales up 20% and consumables, software, and services growing over 27%. Despite posting a net loss of $1.18 million for the quarter, gross profit increased 27% to $9.7 million. The company generated $3.5 million in operating cash flow for the nine months and maintains $6.9 million cash on hand. Management confirmed 2024 guidance with expected sales between $78-82 million, representing 10-15% organic growth. The company expects to complete its going private transaction on November 29, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary

Hamilton Thorne (TSX: HTL), a leading provider in the Assisted Reproductive Technologies (ART) field, has provided an update on its going private transaction with Cradle Acquisition Key points include:

  • The transaction was approved by shareholders on September 17, 2024
  • Final court approval was obtained on September 20, 2024
  • Definitive agreements have been signed for the acquisition of Cook Medical's ART product portfolio
  • All required regulatory approvals have been obtained
  • The transaction and acquisition are expected to close on November 30, 2024
  • Hamilton Thorne's shares will be delisted from the TSX upon closing

The company will also apply to cease being a reporting issuer in Canada.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
Rhea-AI Summary
Hamilton Thorne (HTLZF) to participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference. CEO Kate Torchilin to speak at the event. The company offers precision instruments, software, and services to ART, research, and cell biology markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Hamilton Thorne completes acquisition of Gynetics, strengthening its footprint in the Assisted Reproductive Technology market and expanding product offerings in the European IVF market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of HAMILTON THORNE ORD (HTLZF)?

The current stock price of HAMILTON THORNE ORD (HTLZF) is $1.5914 as of November 22, 2024.

What is the market cap of HAMILTON THORNE ORD (HTLZF)?

The market cap of HAMILTON THORNE ORD (HTLZF) is approximately 245.9M.

What does Hamilton Thorne Ltd. do?

Hamilton Thorne Ltd. is a leading provider of precision instruments, consumables, software, and services in the Assisted Reproductive Technologies (ART) research and cell biology markets.

What recent acquisition has Hamilton Thorne completed?

Hamilton Thorne recently completed the acquisition of Gynetics Medical Products, a leading manufacturer of IVF devices in the global IVF market.

What are the key benefits of the acquisition?

The acquisition of Gynetics strengthens Hamilton Thorne's consumables product offerings, diversifies revenue streams, and enhances customer service quality.

What is Gynetics' revenue and Adjusted EBITDA?

Gynetics had revenues of approximately €4.6 million and Adjusted EBITDA of €2.3 million.

How does the acquisition impact Hamilton Thorne's presence in the European ART market?

The acquisition of Gynetics reinforces Hamilton Thorne's position in the European ART market.

What is the acquisition price for Gynetics?

Hamilton Thorne acquired Gynetics for an enterprise value of approximately €18.3 million.

How was the acquisition of Gynetics financed?

The acquisition of Gynetics was financed through a mix of cash and issuance of Hamilton Thorne stock.

What brands does Hamilton Thorne market its products and services under?

Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event, Microptic, and Gynetics brands.

What is Gynetics known for?

Gynetics is known for being a leading manufacturer of innovative, high-quality IVF devices in the global IVF market.

What are the non-IFRS measures mentioned in the press release?

The non-IFRS measures mentioned in the press release include Adjusted EBITDA, which is used as a measurement to provide additional information to complement IFRS measures.

HAMILTON THORNE LTD ORD

OTC:HTLZF

HTLZF Rankings

HTLZF Stock Data

245.90M
107.69M
27.93%
28.15%
Medical Devices
Healthcare
Link
United States of America
Beverly